Sequencing treatments in FL and MCL. Flow charts outline a proposed sequencing of therapies in FL and MCL based on current approvals and highlighting when to consider CAR T-cells and/or BsAb. In R/R FL, patients should again have an indication for therapy to proceed to next line of treatment. ^This approach is based on the TRIANGLE study.⁷⁹ In situations in which 1L ibrutinib is not available, recommend treatment with cytarabine-containing induction chemoimmunotherapy followed by maintenance rituximab and replacement of ibrutinib with another covalent BTKi if possible. BR, bendamustine rituximab; CD20 Ab, CD20 antibody; RBAC, rituximab, bendamustine, cytarabine.